Stockreport

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Kronos Bio, Inc.  (KRON) 
PDF Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of [Read more]